BOSTON– Encora Therapeutics, a clinical-stage medical technology company developing neuromodulation therapies for movement disorders, announced the appointment of Nadim Yared as Chairman and Chief Executive Officer, effective immediately. Co-founder and former CEO Daniel Carballo will transition to the role of Vice President of Strategy.
Under Yared’s leadership, Encora will focus on advancing late-stage clinical programs, strengthening regulatory and reimbursement pathways, and expanding strategic partnerships to accelerate patient access to its therapy.
“Founding Encora was driven by a commitment to restore independence for movement disorder patients,” said Carballo. “I am proud of what Encora has achieved to date and grateful for the dedication of our team, investigators, and patients. Nadim brings a systems-driven approach to scaling medtech companies and a proven track record of aligning product development with evidence generation and commercialization. I’m excited to remain deeply involved as VP of Strategy, partnering with Nadim to accelerate our therapy to patients.”
“I am honored to join Encora at this pivotal moment,” said Yared. “The team has developed a compelling, patient-centered platform with the potential to meaningfully improve daily function for people with movement disorders. I am committed to advancing rigorous clinical evidence, building scalable commercial pathways, and partnering with clinicians and patients to deliver measurable impact.”
